首页> 外文OA文献 >Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial
【2h】

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

机译:氯吡格雷和阿司匹林联用对非ST段抬高型急性冠脉综合征进行手术血运重建的患者的获益和风险:不稳定型心绞痛中的氯吡格雷可预防复发性缺血事件(CURE)试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antiplatelet therapy and antithrombin therapy have been demonstrated to reduce the risk of cardiac events in patients presenting with acute coronary syndrome, yet all effective therapies also increase the risk of bleeding. In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke. The benefits were consistent among those undergoing percutaneous coronary intervention (PCI) [9.6% for clopidogrel, 13.2% for placebo; relative risk (RR), 0.72; 95% CI, 0.57 to 0.90], coronary artery bypass grafting (CABG) surgery (14.5% for clopidogrel 16.2% for placebo; RR, 0.89; 95% CI, 0.71 to 1.11), and medical therapy only (8.1% for clopidogrel, 10.0% for placebo; RR, 0.80; 95% CI, 0.69 to 0.92; test for interaction among strata, 0.53). For CABG during the initial hospitalization (530 for placebo, 485 for clopidogrel), the frequency of CV death, MI or stroke before CABG was 4.7% for placebo and 2.9% for clopidogrel (RR, 0.56; 95% CI, 0.29 to 1.08). For the entire study, there was a 1% excess of major bleeding but no significant excess of life-threatening bleeding. Among patients undergoing CABG, the rates of life-threatening bleeding were 5.6% for clopidogrel and 4.2% for placebo (RR, 1.30; 95% CI, 0.91 to 1.95; both nonsignificant). The benefits versus risks of early and long-term clopidogrel therapy (freedom from CV death, MI, stroke, or life-threatening bleeding) are similar in those undergoing revascularization (CABG or PCI) and in the study population as a whole. Overall, the benefits of starting clopidogrel on admission appear to outweigh the risks, even among those who proceed to CABG during the initial hospitalization
机译:已证明抗血小板疗法和抗凝血酶疗法可降低患有急性冠状动脉综合征的患者发生心脏事件的风险,但是所有有效的疗法也会增加出血的风险。在不稳定型心绞痛的氯吡格雷预防复发性缺血事件(CURE)试验中,除阿司匹林外,还有12 562例患者被随机分为氯吡格雷或安慰剂治疗,主要结局是心血管(CV)死亡,心肌梗塞(MI)或中风。在接受经皮冠状动脉介入治疗(PCI)的患者中,获益是一致的:氯吡格雷为9.6%,安慰剂为13.2%;相对风险(RR),0.72; 95%CI,0.57至0.90],冠状动脉搭桥术(CABG)(氯吡格雷14.5%,安慰剂16.2%; RR,0.89; 95%CI,0.71至1.11),仅药物治疗(氯吡格雷8.1%,安慰剂为10.0%; RR为0.80; 95%CI为0.69至0.92;层间相互作用的测试为0.53)。对于初次住院期间的CABG(安慰剂为530,氯吡格雷为485),在CABG之前,安慰剂的CV死亡,MI或中风的发生率为安慰剂为4.7%,氯吡格雷为2.9%(RR,0.56; 95%CI,0.29至1.08) 。在整个研究中,主要出血量增加了1%,而威胁生命的出血量则没有明显增加。在接受CABG的患者中,危及生命的出血率氯吡格雷为5.6%,安慰剂为4.2%(RR,1.30; 95%CI,0.91至1.95;两者均无统计学意义)。早期和长期使用氯吡格雷治疗(无心血管死亡,心肌梗死,中风或危及生命的出血)的获益与风险在进行血管重建术(CABG或PCI)的患者以及整个研究人群中相似。总体而言,入院时开始使用氯吡格雷的益处似乎大于风险,即使在初次住院期间接受CABG的患者中也是如此

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号